Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. 1993

S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
Department of Medicine (II), University of Tokyo, Japan.

OBJECTIVE Sonographically guided percutaneous ethanol injection therapy has been used widely in the treatment of hepatocellular carcinoma. However, few reports have been published on the results of this treatment in large numbers of patients. Accordingly, we describe our experience with 146 patients who had this treatment. The study is an update of our previous reports on this subject. METHODS We used ethanol injection, with or without transcatheter arterial embolization, 1048 times in 146 patients who had 242 lesions of hepatocellular carcinoma. In 98 patients, ethanol injection was used to attempt a cure of the disease. In the remaining 48 patients, ethanol injection was used palliatively only to reduce the tumor burden. In most cases, 2-8 ml of absolute ethanol was injected in one treatment session. Patients were given the injections two or three times each week until ethanol was injected throughout the lesion. When tumors were greater than 2 cm in diameter, ethanol was injected into the edges of the lesion. RESULTS Histopathologic examination after treatment in 21 cases showed that the lesion was completely necrotic in 15 cases, 90% necrotic in five cases, and 70% necrotic in the remaining case. Follow-up angiography performed in 69 cases showed no contrast stains in the treated tumors in 60 cases. Elevated serum levels of alpha-fetoprotein decreased in 39 of 43 cases. The 1-, 2-, 3-, 4-, and 5-year survival rates of all 146 patients were 79%, 64%, 46%, 38%, and 38%, respectively. Among 98 patients in whom ethanol injection was used as a potentially curative therapy, these rates were 85%, 70%, 62%, 52%, and 52%, respectively. After ethanol injection, the cancer recurred frequently; the 1-, 2-, 3-, 4-, and 5-year recurrence rates in the potentially curative group were 26%, 38%, 51%, 60%, and 60%, respectively. However, 84% of recurrences were new lesions in different portions of the liver; recurrence of lesions treated by ethanol injection was rare. Major complications of the treatment were peritoneal bleeding in two cases and pleural effusion in one case. CONCLUSIONS Histopathologic examination, angiography, and serum levels of alpha-fetoprotein showed that percutaneous ethanol injection is a valuable treatment of hepatocellular carcinoma. The therapy increased the long-term survival of patients who have this disease.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol

Related Publications

S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
May 1990, Rinsho hoshasen. Clinical radiography,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
August 1993, Hepato-gastroenterology,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
April 1993, International journal of oncology,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
June 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
May 1996, Nihon rinsho. Japanese journal of clinical medicine,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
September 1998, Scandinavian journal of gastroenterology,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
November 1996, Medizinische Klinik (Munich, Germany : 1983),
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
February 2004, International journal of oncology,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
November 1989, The American journal of gastroenterology,
S Shiina, and K Tagawa, and Y Niwa, and T Unuma, and Y Komatsu, and K Yoshiura, and E Hamada, and M Takahashi, and Y Shiratori, and A Terano
October 2001, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!